Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Arbutus Biopharma Corp (ABUS)

NASDAQ
Currency in USD
Disclaimer
2.735
-0.015(-0.55%)
Real-time Data

ABUS Comments

With a market cap around $280 mil, I wonder if Moderna would entertain thoughts of acquiring ABUS. Might be a reasonable price to pay for patent exclusivity, not to mention ABUS pipeline drugs. Just a thought on my part...not based on rumors.
Buy
Moderna has a meeting whit Arbutus this weekend!!!
source?
Any positive updates on Moderna Arbutus meeting
conference today!!
which conference?
Arbutus ceo conferense!
what happened here???
patent with mdra
if you believe in mdrna.. believe in arbutus as well ..think both still have plenty of room for growth
I still need 48 cents. Hope this is a reset and not a teaser.
Sold.... Good luck tomorrow Florin..
thank's!
let's goo Arbutus $$$!20$
sell while you can.
🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣
I was down 12000 sold it 4.40 6000 shares recover my loss.Adiosssss.Good luck with $10 target.
😁i didn't whant to scare you,but target price is 20$!
I hope it keeps going! let's go!.. lol
Arbutus $$$!
yes !moderna declaration about patent!ARBUTUS has the exclusivete about patent!
In the moderna news I just read nothing related to abus patent.
   look on the general overview chart ... It shows and N  click on it .. .it will give you the article
they are playing with the stock...:)
what just happened? Any news?
Not sure but I like it....LOL
"Scientists ask: Without trial data, how can we trust Russia's COVID vaccine?" https://www.investing.com/news/world-news/scientists-ask-without-trial-data-how-can-we-trust-russias-covid-vaccine-2262108
is this gonna go as low as 3$? or should i just buy in now?
Guys hurry up man!!!
where to?:)
where...?? are you selling?
What is update Fl?
Latest Tweet by Acuitas Therapeutics : Our partner, BioNTech SE announced the selection of their lead vaccine candidate against COVID-19 and the start of the next phase of studies. We’re proud that they are using our lipid nanoparticle delivery system. license agreement between Genevant and Arbutus.!!
Latest Tweet by Acuitas Therapeutics : Our partner, BioNTech SE announced the selection of their lead vaccine candidate against COVID-19 and the start of the next phase of studies. We’re proud that they are using our lipid nanoparticle delivery system. license agreement between Genevant and Arbutus.
this stock is a joke...
something big is coming!good luck!
sorry but what are this news about common shares introduction
how is this going to change the game??
https://investor.arbutusbio.com/static-files/aefabd11-fe05-4d41-bfa9-36733bbebbb5
another big news is round the corner.... context to biontech & pfe.... cheers !!
thanks for that info FT.. looks promising.. im in it @ 4.44.. so I got a ways to go.. lol..
Latest Tweet by Acuitas.. Therapeutics : Our partner, BioNTech SE announced the selection of their lead vaccine candidate against COVID-19 and the start of the next phase of studies. We’re proud that they are using our lipid nanoparticle delivery system. license agreement between Genevant and Arbutus.
...
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.